Effects of Pancreatin therapy on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus

Özet

Objectives: Gastrointestinal symptoms (GIS) are more common in individuals with type 2 diabetes mellitus(DM) in comparison to normal population. This study aimed to evaluate the effects of the pancreatin therapyon the GIS in patients with type 2 DM.Methods: This study included patients with type 2 DM admitted to the Gastroenterology Department between February to July 2017. Age, HbA1c, level of C-peptide, triglyceride, antidiabetic treatments, fecal elastase levels were evaluated in the files of all patients. The GIS of the patients, who were considered to sufferfrom the exocrine pancreatic insufficiency, including abdominal pain, bloating, constipation and diarrhea wereevaluated before and after the 25000 IU pancreatin therapy.Results: The study included 35 patients with type 2 DM, the mean age was 59.1±7.6 years, and 24 (68.6%) ofthe patients were female. The exocrine pancreatic insufficiency was detected in 1 (2.9%) of the patients. Priorto the pancreatin therapy, 33 (94.3%) of the patients were determined to have abdominal pain, 34 (97.1%) hadbloating, 33 (94.3%) had constipation and 32 (91.4%) had diarrhea. After the therapy, 29 (82.9%) of the patientswere found to have abdominal pain, 31 (88.6%) had bloating, 31 (88.6%) had constipation and 29 (82.9%) haddiarrhea. GIS including abdominal pain, bloating, constipation and diarrhea were decreased after pancreatintreatment (p=0.015, p<0.001, p=0.001 and p=0.024, respectively).Conclusion: GIS in patients with type 2 DM can be treated with pancreatic enzyme replacement therapy